CD274 and neoplasm: The three responses reported in this study were observed in cancer types that have been previously shown to respond to immunotherapy.47–49 Whether the genes involved in tumour immune evasion, including PD-L1, that have been identified as targets for miR-34a down-regulation play a role in this mechanism remains to be determined.19–21 Two of the three responses occurred after patients were withdrawn from treatment (MRX34 and DEX), following potential pseudo-progression in one, raising the possibility that high-dose DEX pre-medication might suppress immune activation.